Although the mainstay treatment for advanced prostate cancer relies on suppression of AR activity, there is accumulating evidence that potent activation of AR by treating patients with CRPC with high doses of testosterone can also be of therapeutic benefit. This evidence concerns the gene AR and prostate carcinoma.